Compare Gilead Sciences, Inc. (GILD) vs Taskus Inc (TASK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Taskus Inc — how do they compare? Gilead Sciences, Inc. trades at $133.71 (market cap $163.51B), while Taskus Inc trades at $5.95 (market cap $547.18M). The key difference: Gilead Sciences, Inc. is far larger — about 298.8× Taskus Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Taskus Inc pays none. Which is the better fit depends on your goals.
| GILD | TASK | |
|---|---|---|
Market Cap | $163.51B | $547.18M |
Sector | Health | Technology |
52-Week High | $155.80 | $18.21 |
52-Week Low | $108.22 | $4.57 |
Enterprise Value | $178.05B | $942.88M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
TaskUs (TASK) trades at $5.80, up 3.2% on the day, with technical indicators signaling a bullish trend. The stock appears fundamentally undervalued with a P/E of 5.29 and P/S of 0.46, supported by strong profitability metrics including a 37.05% gross margin and 26.52% ROE. Recent quarterly earnings have mostly beaten expectations, and the company announced a new CFO appointment in June 2026, highlighting ongoing corporate development.
The outlook is positive given the stock's significant discount to analyst consensus price targets near $9.50, representing over 60% upside potential. Key risks include potential earnings volatility, as seen in a recent Q1 2026 miss, and execution risks in a competitive outsourcing sector. The bullish analyst consensus and strong cash generation from operations support a constructive view.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →
